A subset of patients with recurrent high-grade gliomas benefits from the anti-angiogenic therapy bevacizumab (BVZ). An increased number of research efforts are performed to develop predictive biomarkers that allow for screening of patients. The immune system plays a crucial role in angiogenesis induction and maintenance. We analysed circulating immune cells in recurrent high-grade glioma patients treated with BVZ (10 mg/kg every 2 weeks) during a prospective bi-centric trial. Blood samples were collected before cycles 1, 3, 5 and 7 to perform flow cytometry analysis of monocytes (classical/intermediate/non-classical/ DRlow/ Tie2+/ VEGFR1+), Myeloid-Derived Suppressor Cells (MDSC) and regulatory T cells (Tregs) as well as a complete blood count. Thirty patients (29 Glioblastoma, 1 anaplastic astrocytoma) were enrolled between September 2012 and January 2014. Median OS and PFS were 9.1 months (6.7 -18.4; 95% CI) and 3.3 months (1. We have recently applied a novel technique, in which high resolution treatment response assessment maps (TRAMs) are calculated from MRIs acquired with a delay of >1 hr, enabling efficient separation between tumor (contrast clearance >1 hr post injection) and treatment-effects (contrast accumulation) with no overlap. The TRAMs have been applied to study 320 patients with primary and metastatic brain tumors and have been validated histologically in 54 resected patients reaching 100% sensitivity and 93% positive-predictive-value to active tumor. Here we studied the advantages of the TRAMs over standard/advanced MRI methodologies in recurrent high grade glioma (rHGG) patients treated with bevacizumab; further, we determined MRI-based response/progression patterns and defined predictors of response for clinical decision making.
MATERIALS AND METHODS: 24 rHGG patients were studied before/ during bevacizumab treatment by standard/delayed-contrast MRI. A unique, semi-automatic segmentation algorithm was developed to enhance sensitivity to subtle enhancement on T1-Gd. The TRAMs, previously shown to efficiently differentiate tumor/non-tumor tissues in brain-tumor patients undergoing conventional treatments, were calculated from delayed-contrast MRIs.
The patients were divided into responders (overall-survival (OS)≥1 year) and non-responders (OS<1 year). The changes in lesions volumes one month after treatment initiation, calculated from standard/delayed-contrast MRIs, were studied as potential predictors of outcome using log-rank analysis and ROC analysis.
RESULTS: Seven patients were responders and seventeen non-responders. Response/Progression patterns were identified from the mean change in lesion volumes, depicted from conventional T1-Gd, delayed contrast MRI and DSC-MRI. Thresholds for early prediction of response were calculated using these sequences. Sensitivity/specificity/positive-predictivevalue/negative-predictive-value were calculated for each predictor, reaching 100%/87.5%/77.8%/100% for TRAMs, 85.7%/87.5%/75%/93.3% for T1-Gd and 75%/78.6%/50%/91.7% for PWI. The benefit of the TRAMs in separating responders/non-responders was further confirmed using log-rank analysis (T1-Gd: p<0.002, TRAMs: p<0.0001, PWI: p<0.02). ROC analysis demonstrated the added value of the TRAMs for prediction of 6 months PFS and 1 year OS. At progression, the increase in lesion-volumes in the TRAMs was 37.5% higher than the increase in conventional T1-Gd (p<0.01), suggesting progression may be depicted more effectively in the TRAMs.
CONCLUSIONS: The benefit of MRI for assessing and predicting response to bevacizumab was demonstrated. The TRAMs increased sensitivity reflects their potential contribution to management of bevacizumabtreated rHGG patients. In glial tumors the immune-escape is an important mechanism to promote invasion and aggressiveness, thus the aim of our study was to investigate the expression of Interferon inducible protein 16 (IFI16) in human gliomas. IFI16 is a member of the p200 human family proteins that share highly conserved repeats at C-terminus which allow them to bind dsDNA and a typical protein-protein interaction domain at their N-terminus. IFI16 gene is located at 1q23.1 chromosome and encodes for three isoforms of IFI16: its functions ranging from transcriptional regulation, apoptosis, cell growth regulation and differentiation. But, the most intriguing function of IFI16 is its role in the immunomodulation of innate and adaptive immunity. IFI16 protein is located in the nucleolar compartment where it is able to activate and fine-tune the transcription, while when it is located in the nucleoplasm is probably inactive. We have studied IFI16 expression in 120 gliomas (40 grade II, 40 grade III and 40 glioblastomas) by immunohistochemistry, using two antibodies against the C-and N-terminus, and molecular biology techniques. All these cases were also evaluated for p53, IDH1(R132H), MGMT methylation status and LOH of chromosomes 1p, 19q, 9p, 17p and 10q. We found a strong nucleolar expression of IFI16 in astrocytic lower grade gliomas and this expression was strictly related to p53 nuclear expression: this co-localization was demonstrated by confocal analysis and suggests a role of IFI16 as tumor suppressor. In grade III gliomas and glioblastomas, instead, IFI16 was mostly expressed in the nucleoplasm: this shift to the inactive form is related to a shorter survival suggesting a role as prognostic factor. In oligodendrogliomas IFI-16 expression was completely absent and it is strictly related to 1p/19q co-deletion, but with intact IFI16 gene, as showed by array-CGH analysis. As a final point, we have characterized tumor inflammatory infiltrates using antibodies against CD3, CD4, CD8, CD68 and FoxP3 related to IFI16 expression and tumor survival. Particularly in glioblastomas we observed a major expression of CD3+/CD4+ lymphocytes in the cases with strong nucleoplasm IFI16 expression and shorter survival; while CD3+/CD8+ cells were present in glioblastomas with nucleolar expression and longer survival, with also a strong activation of both microglia and macrophages, suggesting an active role of IFI16 in immuno-surveillance. In conclusion, this is the first study of IFI16 in gliomas, and we identify IFI16 as a new potential prognostic factor, highlighting its early role in proliferation, malignant progression and immunomodulation of these tumours. INTRODUCTION: The co-deletion of complete chromosome arms 1p and 19q is the hallmark of oligodendroglioma and is related to a favorable clinical outcome. The epidermal growth factor receptor (EGFR) is overexpressed in almost half of glioblastoma multiforme (GBM) and the most common EGFR mutant is EGFRvIII. EGFRvIII expression is an independent and significant unfavorable prognosticator of survival. EGFRvIII and 1p19q co-deletion rarely coexist in the same glioma tumor sample.
P06.15 IFI16 EXPRESSION IN GLIOMAS AND ITS POTENTIAL ROLE

P06.16 EGFRVIII AND 1P19Q CO-DELETION CAN CO-EXIST IN GLIOMAS
MATERIALS AND METHODS: We present two cases of GBMs, characterized by 1p19q co-deletion and the expression of EGFRvIII. In the first one, EGFRvIII was detected by immunohistochemistry (IHC) and in the second one with real time PCR in tumor RNA. 1p19q co-deletion was detected in both cases with DNA analysis (MLPA) of the tumor. Because of the rarity of this coexistence a "deeper" study of the molecular profile of these tumors will be undertaken with next generation sequencing and presented at EANO.
RESULTS: The first patient is a 51yo woman presumably diagnosed with glioblastoma grade IV with an oligodendroglioma component in August 2015. The patient was operated and then concurrent radiation therapy and temozolomide were given. She is now on adjuvant therapy with temozolomide. DNA analysis on tumor sample revealed 1p19q co-deletion and immunohistochemistry undertaken to evaluate her eligibility for the Rindopepimut compassionate use program, revealed EGFRvIII mutation.
The second patient is a 39yo man diagnosed with GBM with an oligodendroglial component in March 2014. He was operated and subsequently treated with temozolomide and radiation therapy. Then, adjuvant temozolomide was administered for 6 months. In February 2015 a recurrence was detected, he underwent a re-operation and the same histological type was revealed. Treatment with bevacizumab and temozolomide was administered for 9 cycles. In November 2015 a new recurrence led to another operation. The tumor this time was described as a grade II-III oligodendroglioma. DNA analysis revealed that the tumor is positive for 1p19q co-deletion and the Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv31/2222792 by guest on 11 April 2019
